Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2016 Nov 25;291(48):25280. doi: 10.1074/jbc.A116.750653

Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells.

Shanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, Travis Nemkov, Brett M Stevens, Biniam Adane, Nabilah Khan, Fred K Hagen, Vinod K Yadav, Subhajyoti De, John M Ashton, Kirk C Hansen, Jonathan A Gutman, Daniel A Pollyea, Peter A Crooks, Clayton Smith, Craig T Jordan
PMCID: PMC5122795  PMID: 27888238

VOLUME 291 (2016) PAGES 21984–22000

The University of Arkansas for Medical Sciences and Dr. Peter A. Crooks have financial interests in melampomagnolide B (MMB) and structurally related analogs discussed in this manuscript. These financial interests have been reviewed and approved in accordance with the university's conflict of interest policies.


Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES